Actively Recruiting
Trastuzumab Deruxtecan Versus Standard Chemotherapy With or Without Radiotherapy for HER2-Expressing Endometrial Cancer as Adjuvant Treatment A Global Phase 3 Randomized Trial
Led by Daiichi Sankyo · Updated on 2026-10-27
710
Participants Needed
86
Research Sites
108 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying the use of Trastuzumab Deruxtecan T-DXd as an adjuvant treatment compared to standard chemotherapy, with or without radiotherapy, in women with newly diagnosed HER2-expressing endometrial cancer. This phase 3, open-label global trial aims to assess the safety and effectiveness of these treatments in participants who have not previously received anticancer therapy. The study focuses on participants with specific stages and various levels of HER2 expression in their cancer. Participants will be randomly assigned to receive either T-DXd at a dose of 5.4 mgkg intravenously every three weeks, with optional radiotherapy, or standard chemotherapy consisting of carboplatin and paclitaxel given every three weeks, with or without radiotherapy or chemoradiotherapy including cisplatin as a radiosensitizer. This comparison will evaluate how well these treatments work as adjuvant therapy following surgery. The study will continue until disease recurrence or other defined endpoints. During the study, participants will be monitored for disease-free survival using imaging reviewed by a blinded independent central review or local histopathologic confirmation, up to about 51 months after randomization. Overall survival will also be tracked up to approximately 63 months. Assessments will include radiographic evaluations and safety monitoring. Participants can expect regular visits for treatment and follow-up over several years to measure outcomes and ensure safety throughout the trial period.
CONDITIONS
Brief Title
A Study of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy for HER2-Expressing (IHC 3+/2+) Endometrial Cancer in Adjuvant Setting
Research Team
C
Contact for Trial Information
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here